Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

Core Insights - Oncolytics Biotech Inc. hosted a key opinion leader (KOL) webinar discussing the clinical data of pelareorep and its role in treating pancreatic and gastrointestinal cancers [1][2] - The CEO emphasized pelareorep as a compelling immunotherapy platform suitable for combination strategies, aiming for registrational development in collaboration with pharmaceutical partners [2] Company Overview - Oncolytics is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that has shown promising results in metastatic breast cancer and pancreatic cancer [3][4] - Pelareorep works by inducing anti-cancer immune responses and converting "cold" tumors into "hot" tumors, enhancing treatment efficacy [3] Clinical Development - Pelareorep has demonstrated synergies with multiple approved oncology treatments, and Oncolytics is advancing combination clinical trials in solid malignancies, particularly in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA [4] - The treatment has shown meaningful survival benefits in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) patients, highlighting an unmet need for effective immunotherapies in this area [6] Mechanism of Action - Translational data from clinical trials indicate that pelareorep replicates in tumors, stimulates chemokine expression, and promotes the expansion of tumor-infiltrating lymphocytes (TILs), correlating with tumor size reduction [6]